| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
The primary targets of Tinostamustine HCl are DNA and histone deacetylases (HDACs). As a dual alkylating agent and HDAC inhibitor, it alkylates DNA, causing cross-linking and DNA damage, while simultaneously inhibiting HDACs, leading to changes in gene expression and chromatin structure. This dual mechanism of action may overcome resistance to other therapeutic agents.
|
|---|---|
| ln Vitro |
In vitro, Tinostamustine HCl has been shown to have potent anti-cancer activity due to its dual mechanism of action. It alkylates DNA and inhibits HDACs, leading to cell cycle arrest and apoptosis in cancer cells. The compound's activity has been confirmed in various in vitro models.
|
| ln Vivo |
In vivo, Tinostamustine HCl has been studied in preclinical models of cancer. Its dual mechanism of action makes it a promising candidate for the treatment of various cancers. However, specific in vivo efficacy data from animal models are limited in the available literature.
|
| Enzyme Assay |
In vitro enzyme or receptor binding assays for Tinostamustine HCl involve measuring its inhibition of HDAC activity and its alkylating activity. HDAC inhibition is measured using a fluorogenic substrate with purified HDAC enzymes. Alkylating activity is assessed by measuring the formation of DNA adducts using biochemical methods.
|
| Cell Assay |
In vitro cell-based assays for Tinostamustine HCl are performed using various cancer cell lines. Cells are treated with the compound, and cell viability, proliferation, and apoptosis are assessed using standard assays. The compound's effects on HDAC activity and DNA damage are evaluated.
|
| Animal Protocol |
In vivo animal experiments for Tinostamustine HCl are conducted using mouse xenograft models of cancer. Mice bearing subcutaneous tumors are treated with the compound, and tumor volume is measured over time. The compound's effects on tumor growth and survival are evaluated.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of Tinostamustine HCl indicate that it has a molecular weight of 451.82 and a molecular formula of C19H29Cl3N4O2. The CAS number is 1793059-58-1. The IUPAC name is 7-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]-N-hydroxyheptanamide;hydrochloride. Powder is stable when stored at -20°C for 3 years.
|
| Toxicity/Toxicokinetics |
Toxicology (toxicology) data for Tinostamustine HCl are characteristic of a dual alkylating agent and HDAC inhibitor. As an anticancer agent, its safety profile is an important consideration. The compound is generally well-tolerated at effective doses in preclinical models. However, its long-term safety profile requires further evaluation.
|
| References |
Establishment and Characterization of a Reliable Xenograft Model of Hodgkin Lymphoma Suitable for the Study of Tumor Origin and the Design of New Therapies. Cancers (Basel). 2018 Oct 31;10(11).
|
| Additional Infomation |
Other information: Tinostamustine HCl is also known as EDO-S101, Minomustine, and 2-Desbutylcarboxy-2-(N-hydroxyheptanamino) Bendamustine Hydrochloride. It is a dual alkylating agent and histone-deacetylase inhibitor (HDACi). Its UNII is QK4ZBS4FPO. The compound is for research use only.
|
| Molecular Formula |
C19H29CL3N4O2
|
|---|---|
| Molecular Weight |
451.82
|
| Exact Mass |
450.135
|
| CAS # |
1793059-58-1
|
| Related CAS # |
1793059-58-1 (HCl);1236199-60-2;
|
| PubChem CID |
134687437
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
28
|
| Complexity |
438
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN1C(=NC2=CC(N(CCCl)CCCl)=CC=C12)CCCCCCC(=O)NO.Cl
|
| InChi Key |
7-(5-(bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)-N-hydroxyheptanamide hydrochloride
|
| InChi Code |
DWGQFQRWFYIINU-UHFFFAOYSA-N
|
| Chemical Name |
EDO-S101 EDO-S 101 EDO-S-101 EDO-S101 HCl EDO-S101 hydrochloride Tinostamustine hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2133 mL | 11.0664 mL | 22.1327 mL | |
| 5 mM | 0.4427 mL | 2.2133 mL | 4.4265 mL | |
| 10 mM | 0.2213 mL | 1.1066 mL | 2.2133 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA